Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...
A practical guide to Perplexity Computer: multi-model orchestration, setup and credits, prompting for outcomes, workflows, ...
Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its ...
Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Hosted on MSN
Recursion Pharmaceuticals (RXRX) beats stock market upswing: What investors need to know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.11, moving +1.63% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.11%.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
RXRX is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.07 since the market last closed. This is a 2.02 ...
During his 25 years working as a software engineer, Andy Weir wrote two novels that never found an audience. He also wrote a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results